All In Biotech

Drug Trial Radar · NCT02855892

A Phase II Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Patients With BPH

A Randomized, Placebo-controlled, Single-blind, Parallel Design, Multi-center, Phase II Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Patients With Benign Prostatic Hyperplasia (BPH)

Last checked: Nov 19, 2026Latest source record: Mar 4, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 161 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

161

Actual

Start

Oct 2015

Primary completion

Oct 2016

Study completion Oct 2016

Sponsor

Lead sponsor
GemVax & KaelIndustry
Sponsor type
Industry
First posted
Aug 4, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial is designed as a randomized, placebo-controlled, single-blind, parallel design, multi-center, phase 2 clinical trial to evaluate the efficacy and safety of GV1001 in patients with benign prostatic hyperplasia. Eligible subjects are randomized into a group out of the three study groups and a placebo group after four weeks of placebo run-in period. Placebo run-in period is concurrently proceeded as a wash-out period for previous treatment of benign prostatic hyperplasia, and a placebo is administered intradermally twice with two-week interval during this period. After that, the randomized subjects receive a study drug and a placebo intradermally seven times with two-week interval by visiting at Week 0, 2, 4, 6, 8, 10, and 12. After the treatment period, the subjects additionally visit at Week 13 and 16, and the efficacy is evaluated at Week 4, 8, 12, 13, and 16, and the safety is evaluated over the 16-week period.

Conditions

  • Benign Prostatic Hyperplasia (BPH)

Interventions

  • PlaceboOther

  • GV1001Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluation of doses of GV1001 by comparing the level of change in IPSS scores in three study groups to a control group.Time frame: at Week 0, 4, 8, 12, 13, and 16

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Inje University Busan Paik Hospital

    Busan, South Korea

  • Keimyung University Dongsan Medical Center

    Daegu, South Korea

  • Chung-ang University Hospital

    Seoul, South Korea

  • Eulji General Hospital

    Seoul, South Korea

  • Severance Hospital

    Seoul, South Korea

  • Hanyang University Guri Hospital

    Guri-si, Gyeonggi-do, South Korea

  • Seoul National University Bundang Hospital

    Seongnam-si, Gyeonggi-do, South Korea

  • Dongguk University Gyeongju Hospital

    Gyeongju, Gyeongsangbuk-do, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.